Comment from Eli Lilly and Company

Summary: Eli Lilly and Company supports the FDA's pilot program for AI-enabled optimization of early-phase clinical trials and provides detailed recommendations on trial types, use cases, and evaluation metrics. The company advocates for a structured, risk-based approach that prioritizes regulatory relevance, data integrity, and pre-competitive collaboration while ensuring human-in-the-loop oversight.